Author

C. J. Teng

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Clinical trial Oct 2026

Felzartamab plus lenalidomide-dexamethasone versus lenalidomide-dexamethasone for relapsed or refractory multiple myeloma: an open-label, parallel-controlled, randomised, phase 3 trial.

BACKGROUND Complement-dependent cytotoxicity (CDC) of CD38 monoclonal antibodies has been associated with infusion-related reactions and might contribute to reduced clinical efficacy of CDC-reliant CD38 antibodies, particularly in patients with relapsed or refractory multiple myeloma with 1q21+. We aimed to evaluate fe...

Hai-Yan He, J. Shang, Ya-Fei Wang et al. · The Lancet Haematology · 0 citations

Open access Sep 2026

Treatment of Mantle Cell Lymphoma in Asia: Updated Consensus from the Asian Lymphoma Study Group.

Up-to-date expert consensus from the Asian Lymphoma Study Group (ALSG) on treatment recommendations for mantle cell lymphoma (MCL) in Asia is reported, indicating there is no one-size-fits-all approach and resource-stratified approaches should be considered.

Jason Yongsheng Chan, Soon Thye Lim, C. Ong et al. · Cancer research and treatmen... · 0 citations